

AHI Annual General Meeting Update

Advanced Health Intelligence Ltd (ASX:AHI) ('AHI' or 'the Company') wishes to advise that the Company's Annual General Meeting ('AGM') to be held on Friday, 29 November 2024, at 1pm AWST, at the Office of Steinepreis Paganin at Level 14, QV1 Building, 250 St George's Terrace, Perth WA 6000, will be proceeding as planned.

Unfortunately, the Company's 2024 Annual Report is yet to be lodged, and will not be provided to shareholders before the AGM. The Company has had to deal with a number of technical accounting issues, which has delayed the completion and audit of the Company's 2024 Annual Report.

As the Company's 2024 Annual report will not be available before its AGM, the AGM will be adjourned to the extent required for the Annual Report to be considered, and for non-binding resolution 1 (which relates to the adoption of the Remuneration Report) to be put to shareholders, at such date that the Company's shareholders have had a reasonable opportunity to consider the Company's 2024 Annual Report. The Company expects to lodge its 2024 Annual Report by late December 2024, and to resume the AGM in January 2025.

All other items of business contained within the Company's Notice of AGM will be considered and put to shareholders on 29 November 2024. The Company will provide shareholders with an update once the Annual Report has been lodged and a date for the resumption of the AGM has been confirmed.

This announcement has been approved for release by the Company's Chairman and Chief Executive Officer.

For more information, contact:

Scott Montgomery Chief Executive Officer Advanced Health Intelligence Ltd E: admin@ahi.tech Vlado Bosanac Founder/Head of Strategy Advanced Health Intelligence Ltd E: admin@ahi.tech

About Advanced Health Intelligence Ltd

Advanced Health Intelligence (AHI) delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes.

Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:

- Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
- Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
- Transdermal Optical Imaging is used to return vital signs and provide risk estimates for cardiovascular disease.



- On-device dermatological skin identification across 588 skin conditions across 133 categories (Inc. Melanoma); and
- Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.

Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI's technology is at the forefront of innovation and the needs of our consumers.

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.

For more information, please visit: www.ahi.tech